The evolving use of biologicals in the treatment and prevention of infectious diseases.
Although the studies presented in this symposium illustrate the benefits of biologicals in treating patients whose immune systems have been compromised by congenital or acquired immunodeficiencies, it is likely that in the future these agents will also play a role in the management of immunocompetent persons suffering from complications of infection. The insights resulting from the work discussed here provide a strong basis for making that possibility a reality.
Pizzo
P A
PA
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D001688:Biological Products / Q000627:therapeutic use*; D006105:Granulomatous Disease, Chronic / Q000150:complications; D006801:Humans; D017053:Infection Control / Q000379:methods*; D007239:Infections / Q000628:therapy*; D009369:Neoplasms / Q000150:complications; D011183:Postoperative Complications / Q000517:prevention & control; D014947:Wounds and Injuries / Q000150:complications
D001688:Biological Products